Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLY-RX vs AKNE-MYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
POLY-RX is a fictional drug with no established mechanism of action.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
No FDA-approved or off-label indications exist for a non-existent drug.
Topical treatment of acne vulgaris
Not established. Data insufficient for dosing recommendations.
Topical application of 2% solution twice daily to affected areas.
12-15 hours; prolonged in renal impairment (up to 30 hours); no dose adjustment needed for mild-moderate renal impairment
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Not characterized for a non-existent drug.
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Renal 80% unchanged, biliary/fecal 20%
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
92% bound to albumin
Bound primarily to albumin (10-20%)
0.8 L/kg; indicates moderate tissue distribution
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
Oral: 75% (with food decreases absorption); IM: 100%
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
No data available for renal impairment.
No dosage adjustment required for topical use; systemic absorption negligible.
No data available for hepatic impairment.
No dosage adjustment required for topical use; systemic absorption negligible.
No established pediatric dosing.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
No specific geriatric dosing guidelines.
No specific adjustments; use with caution due to potential increased skin sensitivity.
None
None
No clinical warnings applicable to a non-existent drug.
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
None established for a non-existent drug.
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
Avoid grapefruit and grapefruit juice as it may increase levels of some components. Take with food if gastrointestinal upset occurs, but avoid high-fat meals that may alter absorption. Limit alcohol consumption as it may increase hepatotoxicity risk.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
Insufficient data in humans; animal studies not available. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on mechanism. Second/third trimester: unknown.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
No data on excretion in human milk; M/P ratio unknown. Caution advised; consider risk to infant versus benefit to mother.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. Monitor clinical response and adjust based on tolerability.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
POLY-RX is a multi-drug regimen; ensure adherence to all components to prevent subtherapeutic effect and resistance. Monitor renal function for all components, especially if any are renally excreted. Check for drug-drug interactions, particularly with CYP450 inducers/inhibitors. Adjust doses in hepatic or renal impairment per individual drug guidelines.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
Take all medications exactly as prescribed at the same time each day.,Do not skip doses or stop taking any component without consulting your doctor.,Report any signs of allergic reaction, severe nausea, or unusual bleeding.,Keep a list of all medications you take, including over-the-counter and supplements.,Store medications in a cool, dry place away from children.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLY-RX vs AKNE-MYCIN, answered by our medical review team.
POLY-RX is a Topical Antibiotic that works by POLY-RX is a fictional drug with no established mechanism of action.. AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLY-RX and AKNE-MYCIN depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLY-RX is: Not established. Data insufficient for dosing recommendations.. The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLY-RX and AKNE-MYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLY-RX is classified as Category C. Insufficient data in humans; animal studies not available. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on mechanism. Second. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.